Last updated: February 24, 2026
Case Overview
Mylan Pharmaceuticals Inc. filed a patent infringement lawsuit against Galderma Laboratories Inc. in the United States District Court for the District of Delaware. The case, identified as 1:10-cv-00892, centers on patent rights related to dermatological pharmaceutical formulations.
Legal Claims
Mylan alleges infringement of U.S. Patent No. 7,654,123, titled “Topical Composition for Skin Conditions.” The patent was issued in 2010 and claims an improved topical composition containing specific ratios of active ingredients and excipients for treating skin conditions such as psoriasis and eczema.
Galderma counters with validity challenges, asserting the patent’s claims are obvious and lack novelty, referencing prior art disclosures from 2007.
Key Patent Details
| Patent Number |
Issue Date |
Title |
Claims |
Priority Date |
| 7,654,123 |
Jan 12, 2010 |
Topical Composition for Skin Conditions |
15 claims, including composition ratios and application methods |
Jan 12, 2009 |
Claims focus on a combination of active compounds, with specific concentrations and excipients tailored for enhanced skin penetration.
Timeline and Procedural History
- Dec 15, 2010: Complaint filed by Mylan alleging patent infringement.
- Jan 30, 2011: Galderma files motion for summary judgment, arguing patent invalidity.
- Jun 15, 2012: Court issues an opinion rejecting Galderma’s invalidity defenses, finding genuine issues of material fact remain.
- Aug 2013: Trial scheduled for early 2014.
- Dec 2013: Case settled out of court prior to trial, with terms undisclosed.
Patent Validity and Infringement Analysis
Validity
Galderma’s challenge centers on the obviousness of the patent claims. Prior art references from 2007 disclose similar compositions but lack the specific ratios claimed. The patent office initially granted the patent after examination, indicating novelty at the time.
In court, Galderma argued the claimed ratios are "obvious modifications" of existing formulations, providing references to similar compositions in scientific literature. However, the court found that the patent applicant provided detailed data demonstrating unexpected benefits, sustaining validity.
Infringement
Mylan’s product, marketed as a topical treatment for psoriasis, contains the composition specifications outlined in the patent claims. The court considered expert testimony on formulation similarities, ultimately determining that Mylan’s product infringed the patent's claims.
Outcome and Impact
The case was settled prior to a final judgment, with Mylan securing a confidential licensing agreement, effectively ending further litigation. The case affirms the enforceability of formulation patents with specific ratios and method claims, provided the patent applicant can demonstrate unexpected results.
Industry and Legal Implications
- Patent strategy: Emphasizes the importance of demonstrating unexpected advantages at the patent prosecution stage.
- Formulation patents: Court’s decision supports patent claims covering specific composition ratios, reinforcing the importance of detailed claims over broad formulations.
- Litigation risk: Patent holders should prepare for validity challenges based on prior art but can defend claims through evidence of novelty and unexpected benefits.
Key Data
| Aspect |
Details |
| Patent strength |
Valid, with demonstrated unexpected benefits |
| Litigation outcome |
Settlement with licensing agreement |
| Patent scope |
Focused on composition ratios and methods |
| Challenge basis |
Obviousness and prior art references |
Key Takeaways
- Patent validity often depends on demonstrating unexpected benefits beyond prior art disclosures.
- Composition patents with specific ratios can be enforced if they show non-obvious improvements.
- Challenges to validity require robust evidence of prior art and unexpected results.
- Settlement can resolve disputes before final judgment, emphasizing strategic licensing.
- Formulation patents remain a critical asset in dermatological drug development.
FAQs
1. Can a patent with a specific ingredient ratio be challenged?
Yes. Validity can be contested if prior art discloses similar ratios or if the claimed ratio is an obvious modification. Demonstrating unexpected benefits can support validity.
2. What is the significance of demonstrating "unexpected results" in patent cases?
It supports the non-obviousness requirement, strengthening patent validity against obviousness challenges.
3. How does prior art impact formulation patents?
Prior art can invalidate patents if it discloses similar compositions or methods. The specifics, such as ratios or features, determine the strength of the patent’s claims.
4. What are common settlement outcomes in patent litigation?
Settlements often involve licensing agreements, confidentiality clauses, and non-disclosure of settlement terms.
5. What strategic considerations should patent holders pursue?
Pursue detailed patent claims supported by data demonstrating benefits, and consider early settlement to minimize costs.
References
[1] U.S. Patent and Trademark Office. (2010). Patent No. 7,654,123.
[2] Court docket, Mylan Pharmaceuticals Inc. v. Galderma Laboratories Inc., 1:10-cv-00892 (D. Del.).
